Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

Cardiac Safety Study of Brentuximab Vedotin (SGN-35)

See Locations Near You

Summary

The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Relapsed or refractory CD30-positive malignancy
Adequate organ function
ECOG performance status <2

Exclusion Criteria:

Cardiac abnormalities (abnormal rhythm, history of significant cardiac event)
Current diagnosis of primary cutaneous ALCL
Acute or chronic graft-versus-host disease
Prior hematopoietic stem cell transplant within specified timeframe

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT01026233

Recruitment Status:

Completed

Sponsor:

Seagen Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 9 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States
City of Hope National Medical Center
Duarte California, 91010, United States
Stanford Cancer Center
Stanford California, 94305, United States
University of Miami Hospital and Clinics, Miller School of Medicine
Miami Florida, 33136, United States
Cardinal Bernardin Cancer Center / Loyola University Medical Center
Maywood Illinois, 60153, United States
New York University Cancer Institute
New York New York, 10016, United States
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States
Baylor University Medical Center
Dallas Texas, 75246, United States
University Hospital of Cologne
Koln , 50924, Germany
Load More

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

52

Study ID:

NCT01026233

Recruitment Status:

Completed

Sponsor:


Seagen Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider